Sildenafil

Sildenafil (UK-92480) is a potent, competitive, and selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), the enzyme principally responsible for hydrolytic degradation of cGMP in vascular smooth muscle, the corpus cavernosum, and the pulmonary vasculature. The compound was synthesized at the Pfizer Global Research and Development laboratories in Sandwich, Kent, United Kingdom in 1989 as part of a medicinal chemistry program targeting selective PDE5 inhibition for the treatment of angina pectoris and hypertension. Phase I clinical trials revealed limited antianginal efficacy but a pronounced and reproducible effect on penile erection, prompting repositioning toward erectile dysfunction. Sildenafil received United States Food and Drug Administration (FDA) approval on 27 March 1998 as the first oral pharmacotherapy for erectile dysfunction (marketed as Viagra) and subsequently received FDA approval in June 2005 for the treatment of World Health Organization Group I pulmonary arterial hypertension (marketed as Revatio).

The pharmacological mechanism is inhibition of PDE5 at the catalytic site with an IC50 of approximately 3.5 nanomolar and selectivity over PDE1 through PDE4 of 80- to 19,000-fold, with approximately 10-fold selectivity over the structurally related retinal PDE6, the latter accounting for the dose-dependent visual disturbances observed clinically [1, 2]. PDE5 inhibition potentiates the nitric oxide (NO)/soluble guanylyl cyclase (sGC)/cGMP signaling cascade: in tissues where NO release occurs (penile corpus cavernosum during sexual stimulation, pulmonary vascular endothelium), sildenafil amplifies the downstream smooth muscle relaxation by preventing cGMP breakdown. The compound does not directly initiate smooth muscle relaxation in the absence of NO signaling, a pharmacological distinction that differentiates PDE5 inhibitors from direct NO donors and from soluble guanylyl cyclase stimulators.

Pharmacokinetics are characterized by rapid oral absorption (time to peak plasma concentration approximately 60 minutes under fasting conditions), moderate absolute oral bioavailability of approximately 41 percent (limited by hepatic first-pass metabolism), a plasma elimination half-life of approximately 3 to 5 hours, and high plasma protein binding of approximately 96 percent [3, 4]. Metabolism is predominantly hepatic via cytochrome P450 3A4 (CYP3A4, major pathway) and CYP2C9 (minor pathway), producing the active N-desmethyl metabolite (UK-103,320) that retains approximately 50 percent of the parent compound potency at PDE5 and has a similar terminal half-life [3]. The CYP3A4 dependence creates clinically significant drug-drug interactions with strong CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole, erythromycin), which can elevate sildenafil plasma concentrations by 3- to 11-fold.

The clinical evidence base spans two FDA-approved indications (erectile dysfunction and pulmonary arterial hypertension) and multiple investigational applications including Raynaud phenomenon, heart failure, altitude sickness, and neuroprotection. The SUPER-1 trial in 278 patients with pulmonary arterial hypertension demonstrated significant improvement in six-minute walk distance across all sildenafil dose groups (20, 40, and 80 mg three times daily) compared to placebo [5]. A 2024 dose-ranging trial by Hoeper et al. further demonstrated dose-dependent benefit, with the 80 mg three times daily group achieving a median gain of 52 meters in six-minute walk distance [6]. Preclinical pharmacology has established cardioprotective effects against ischemia-reperfusion injury through mitochondrial ATP-sensitive potassium channel opening, neuroprotective effects in rodent stroke and neurodegeneration models through cGMP-mediated anti-apoptotic signaling, and anti-inflammatory effects through suppression of NF-kappaB-driven cytokine release.

The compound is well tolerated at approved doses. Principal adverse events are headache (16 percent), flushing (10 percent), dyspepsia (7 percent), nasal congestion (4 percent), and dose-dependent visual disturbances (chromatopsia, increased light sensitivity) reflecting PDE6 cross-inhibition in retinal photoreceptors [7]. The critical safety concern is the absolute contraindication with organic nitrates and nitric oxide donors, where co-administration produces synergistic and potentially fatal hypotension through additive cGMP-mediated vasodilation [8]. This monograph reviews the chemistry, synthesis, and structural pharmacology of sildenafil; the molecular mechanism across PDE isoforms; comprehensive human pharmacokinetics; the clinical evidence base across approved and investigational indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five PDE5 inhibitor and vasodilator alternatives against sildenafil on five competency standards.